RIAS
BBIO icon

Rachor Investment Advisory Services’s BridgeBio Pharma BBIO Stock Holding History

Rachor Investment Advisory Services’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40
Closed -$2.97K – 231
2026
Q1 		$2.97K Sell
40
-4
-9% -$290 ﹤0.01% 208
2025
Q4 		$3.37K Buy
+44
New +$2.89K ﹤0.01% 186

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Rachor Investment Advisory Services's BBIO Position: Q2 2026 in Review

Rachor Investment Advisory Services sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 40 shares — an estimated $2.97K sold.

Rachor Investment Advisory Services first reported a position in BBIO in Q4 2025 and held it in 2 quarters. The position peaked at $3.37K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Rachor Investment Advisory Services reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Rachor Investment Advisory Services sold 40 BridgeBio Pharma shares in Q2 2026, an estimated $2.97K.
  • Rachor Investment Advisory Services first reported a position in BridgeBio Pharma in Q4 2025 and held it in 2 quarters.
  • Rachor Investment Advisory Services's BridgeBio Pharma position peaked at $3.37K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Rachor Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.